Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 11:14:1811-1820.
doi: 10.2147/NDT.S151802. eCollection 2018.

Risperidone for children and adolescents with autism spectrum disorder: a systematic review

Narong Maneeton  1 , Benchalak Maneeton  1 , Suwannee Putthisri  2 , Pakapan Woottiluk  3 , Assawin Narkpongphun  1 , Manit Srisurapanont  1
Affiliations

Risperidone for children and adolescents with autism spectrum disorder: a systematic review

Narong Maneeton et al. Neuropsychiatr Dis Treat. .

Abstract

Background: Various clinical trials suggested that risperidone was beneficial in the treatment of autism spectrum disorder (ASD) in children and adolescents.

Objective: The aim of this systematic review was to determine the efficacy, acceptability and tolerability of risperidone in the treatment of children and adolescents with ASD.

Data sources: The databases of Scopus, PubMed, CINAHL and Cochrane Controlled Trials Register were searched in February 2017.

Study eligibility criteria participants and interventions: Eligible RCTs of risperidone in the treatment of child and adolescent patients with ASD. Languages were not restricted.

Study appraisal and synthesis methods: The full-text versions of relevant studies were thoroughly assessed and extracted. The primary efficacy of outcome was the pooled response rate and the pooled mean changed scores of the standardized rating scales for ASD.

Results: A total of 372 randomized subjects from seven RCTs were included in this review. In acute treatment, the pooled mean change score of the Aberrant Behavior Checklist for irritability subscale (ABC-I) and response rate for the risperidone-treated group had a greater significance than that of the placebo-treated group. In the long-term treatment, the pooled mean change score of the CARS in the risperidone-treated group was significantly greater than that in the placebo-treated group. According to the discontinuation phase, the overall pooled relapse rate of the risperidone-treated group was significantly less than that of the placebo-treated group. The rates of pooled overall discontinuation and discontinuation due to adverse events rates were not different between the two groups in acute and long-term treatments.

Limitations: A small study was included in the current review.

Conclusion: In relation to the current systematic review, risperidone is efficacious in the treatment of symptoms in children and adolescents with ASD. Although its acceptability is comparable to placebo, treatment with risperidone is well tolerated in children and adolescents with ASD.

Keywords: ABC; Aberrant Behavior Checklist; CARS; Childhood Autism Rating Scale; acceptability; efficacy; tolerability.

PubMed Disclaimer

Conflict of interest statement

Disclosure NM received travel reimbursement from Lundbeck and Pfizer. BM received honoraria and/or travel reimbursement from Lundbeck, Pfizer and Servier. MS received honoraria from Lundbeck and Sumitomo Dainippon Pharma. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Flow diagram of the study. Abbreviation: EU-CTR, EU Clinical Trials Register.
Figure 2
Figure 2
Summary of risk of bias in RCTs of risperidone vs placebo in children and adolescents with ASD. Abbreviations: ASD, autism spectrum disorder; RCTs, randomized controlled trials.
Figure 3
Figure 3
Forest plot of comparison of RR (95% CI) for clinical response rates of risperidone vs placebo in children and adolescents with ASD in acute treatment. Abbreviations: ASD, autism spectrum disorder; df, degrees of freedom; M–H, Mantel–Haenszel; RR, relative risk.
Figure 4
Figure 4
Forest plot of comparison of mean change scores from baseline of ABC-Iscores (95% CI) of risperidone vs placebo in children and adolescents with ASD in acute treatment. Abbreviations: ABC-I, Aberrant Behavior Checklist for irritability subscale; ASD, autism spectrum disorder; df, degrees of freedom; IV, inverse variance.
Figure 5
Figure 5
Forest plot of comparison of mean change scores from baseline of CARS scores (95% CI) of risperidone vs placebo in children and adolescents with ASD in long-term treatment. Abbreviations: ASD, autism spectrum disorder; CARS, Childhood Autism Rating Scale; df, degrees of freedom; IV, inverse variance.
Figure 6
Figure 6
Forest plot of comparison of RR (95% CI) for a relapse rate of risperidone vs placebo in children and adolescents with ASD in discontinuation treatment. Abbreviations: ASD, autism spectrum disorder; df, degrees of freedom; M–H, Mantel–Haenszel; RR, relative risk.
See this image and copyright information in PMC

References

    1. Hill AP, Zuckerman KE, Hagen AD, et al. Aggressive behavior problems in children with autism spectrum disorders: prevalence and correlates in a large clinical sample. Res Autism Spectr Disord. 2014;8(9):1121–1133. - PMC - PubMed
    1. Soke GN, Rosenberg SA, Hamman RF, et al. Brief report: prevalence of self-injurious behaviors among children with autism spectrum disorder – a population-based study. J Autism Dev Disord. 2016;46(11):3607–3614. - PMC - PubMed
    1. Schreibman L. Intensive behavioral/psychoeducational treatments for autism: research needs and future directions. J Autism Dev Disord. 2000;30(5):373–378. - PubMed
    1. Ospina MB, Krebs Seida J, Clark B, et al. Behavioural and developmental interventions for autism spectrum disorder: a clinical systematic review. PLoS One. 2008;3(11):e3755. - PMC - PubMed
    1. Spreckley M, Boyd R. Efficacy of applied behavioral intervention in preschool children with autism for improving cognitive, language, and adaptive behavior: a systematic review and meta-analysis. J Pediatr. 2009;154(3):338–344. - PubMed